Article Text
Abstract
Levodopa reduces the symptoms of Parkinson’s disease, but might it hasten neurodegeneration? A randomized placebo controlled trial evaluated 361 patients with early Parkinson’s disease who received varying amounts of carbidopa-levodopa or a matching placebo for 40 weeks after which treatment was withdrawn for 2 weeks. The severity of parkinsonism increased more in the placebo group than in those receiving levodopa. Interestingly, neuroimaging studies done to assess striatal dopamine transporter density suggested that levodopa perhaps accelerates the loss of nigrostriatal dopamine nerve terminals. These contrasting results mean that our question remains unanswered.
New England Journal of Medicine 2004, 351, 2498–508.
Research done on over 100 patients and controls in Rochester, USA and Japan identifies NMO-IgG as a specific serum marker autoantibody of neuromyelitis optica (Devic’s disease). This condition needs to be differentiated from multiple sclerosis for several reasons but also because the treatment for the two can vary. Immunosuppressive drugs
Statistics from Altmetric.com
Other content recommended for you
- The role of DAT-SPECT in movement disorders
- Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels
- Present and future drug treatment for Parkinson’s disease
- [123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease
- Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
- Dopamine transporter imaging with [123I]-β-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson’s disease
- Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease
- Extrastriatal dopaminergic changes in Parkinson’s disease patients with impulse control disorders
- Initial management of Parkinson’s disease
- Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease